Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0812 in Rheumatoid Arthritis
NCT00542022Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2004
- Primary completion
- May 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing MK0812 with Placebo (2 arms). Primary endpoint: Change from Baseline in Swollen Joint Count at 12 weeks. Started Jun 2004; status: completed.
02
Drugs
mk-0812
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00542022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00542022.